Journal Information
Vol. 58. Issue 3.
Pages 219-227 (March 2022)
Download PDF
More article options
Vol. 58. Issue 3.
Pages 219-227 (March 2022)
Original Article
Full text access
Impact of Obstructive Sleep Apnea on Gestational Diabetes Mellitus
Impacto de la apnea obstructiva del sueño en la diabetes mellitus gestacional
Alberto Alonso-Fernándeza,b,c,
Corresponding author

Corresponding author.
, María Cerdá Moncadasd, Ainhoa Álvarez Ruiz De Larrinagae,f, Andrés Sánchez Baróng, Mercedes Codina Marceth, Paula Rodríguez Rodríguezf, Ana Victoria Gil Gómezi, María P. Giménez Carrerob, Carla Pía Martínezf, José Pablo Cubero Maríni, Mónica de la Peñaa,b,c, Antonia Barcelób,c,j, Daniel Morell-Garciab,j, Javier Pierolab,c, José Antonio Peña Zarzab,k, Joaquín Durán Cantollac,e,f, José María Marín Trigoc,g,i, Joan B. Sorianol, Francisco García-Ríoc,m
a Department of Pneumology, Hospital Universitario Son Espases, Palma de Mallorca, Spain
b Institut d’Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain
c Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
d Department of Pneumology, Hospital de Manacor, Palma de Mallorca, Spain
e Sleep Unit, Hospital Universitario de Araba, Vitoria, Spain
f Instituto de Investigación BIOARABA, Vitoria, Spain
g Department of Pneumology, Hospital Universitario Miguel Servet, Zaragoza, Spain
h Department of Endocrinology and metabolism, Hospital Universitario Son Espases, Palma de Mallorca, Spain
i Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain
j Department of Clinical Analysis, Hospital Universitario Son Espases, Palma de Mallorca, Spain
k Department of Pediatrics, Hospital Universitario Son Espases, Palma de Mallorca, Spain
l Hospital Universitario de la Princesa-Universidad Autónoma de Madrid, Madrid, Spain
m Department of Pneumology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
Ver más
This item has received
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Additional material (1)

Obstructive sleep apnea (OSA) increases the risk of type 2 diabetes, and hyperinsulinemia. Pregnancy increases the risk of OSA; however, the relationship between OSA and gestational diabetes mellitus (GDM) is unclear. We aimed (1) to evaluate OSA prevalence in GDM patients; (2) to assess the association between OSA and GDM; and (3) to determine the relationships between sleep parameters with insulin resistance (IR).


A total of 177 consecutive women (89 with GDM, 88 controls) in the third trimester of pregnancy underwent a hospital polysomnography. OSA was defined when the apnea-hypopnea index (AHI) was ≥5h−1.


Patients with GDM had higher pregestational body mass index (BMI) and neck circumference than controls, but no differences in snoring or OSA-symptoms, or AHI (3.2±6.0 vs. 1.9±2.7h−1, p=.069). OSA prevalence was not significantly different in both groups. We did not identify OSA as a GDM risk factor in the crude analysis 1.65 (95%CI: 0.73–3.77; p=.232). Multiple regression showed that total sleep time (TST), TST spent with oxygen saturation<90% (T90), and maximum duration of respiratory events as independent factors related with homeostasis model assessment of IR, while T90 was the only independent determinant of quantitative insulin sensitivity check index.


OSA prevalence during the third trimester of pregnancy was not significantly different in patients with GDM than without GDM, and no associations between OSA and GDM determinants were found. We identified T90 and obstructive respiratory events length positive-related to IR, while TST showed an inverse relationship with IR in pregnant women.

Obstructive sleep apnea
Sleep apnea
Insulin resistance

La apnea obstructiva del sueño (AOS) aumenta el riesgo de diabetes tipo 2 e hiperinsulinemia. El embarazo aumenta el riesgo de AOS; sin embargo, la relación entre la AOS y la diabetes mellitus gestacional (DMG) no está clara. Nuestros objetivos fueron (1) evaluar la prevalencia de AOS en pacientes con DMG; (2) evaluar la asociación entre la AOS y la DMG; y (3) determinar las relaciones entre los parámetros del sueño y la resistencia a la insulina (RI).


Un total de 177 mujeres seleccionadas consecutivamente (89 de ellas con DMG, 88 controles) en el tercer trimestre del embarazo se sometieron a una polisomnografía hospitalaria. Se clasificó como AOS un índice de apnea-hipopnea (IAH) de ≥5h-1.


Las pacientes con DMG presentaban un índice de masa corporal (IMC) pregestacional y una circunferencia del cuello más altos que los controles, pero no hubo diferencias en los ronquidos, otros síntomas de AOS o el IAH (3,2±6,0 frente a 1,9±2,7h-1, p=0,069). La diferencia en la prevalencia de AOS entre ambos grupos no fue significativa. No identificamos la AOS como un factor de riesgo de DMG en el análisis bruto (1,65; IC del 95%: 0,73-3,77; p=0,232). Mediante regresión múltiple se determinó que el tiempo total de sueño (TST), el TST pasado con una saturación de oxígeno <90% (T90) y la duración máxima de los eventos respiratorios eran factores independientes relacionados con el Homeostasis Model Assessment of IR (HOMA-IR), mientras que el T90 fue el único determinante independiente del Quantitative Insulin Sensitivity Check Index (QUICKI).


La diferencia de prevalencia de AOS durante el tercer trimestre del embarazo no fue significativa entre las pacientes con DMG y aquellas sin DMG, y no se encontraron asociaciones entre los factores asociados a AOS y DMG. Identificamos que la T90 y la duración de los eventos respiratorios obstructivos estaban relacionados positivamente con la RI, mientras que el TST mostró una relación inversa con la RI en las mujeres embarazadas.

Palabras clave:
Apnea obstructiva del sueño
Apnea del sueño
Resistencia a la insulina
Full Text

Gestational diabetes mellitus (GDM), defined as glucose intolerance that is first detected during pregnancy, is a major public health burden with prevalence ranging from 1% to 14%. Moreover, it is a well-established risk factor for adverse maternal and infant health outcomes, including preeclampsia, cesarean delivery, fetal macrosomia, and fetal death, as well as long-term risk of obesity, metabolic syndrome, and diabetes mellitus in both mother and offspring. Numerous studies have identified risk factors for GDM, such as advance maternal age, previous GDM, member of some ethnic groups, and obesity.1–4

Obstructive sleep apnea (OSA) is a common disorder characterized by the presence of repetitive episodes of total or partial airflow interruption in the upper airway during sleep.5 Prevalence of OSA during pregnancy increases due to some physiological changes, such as weight gain, hormonal changes, or modifications in the upper airway.6–8

Previous studies suggest a possible association between OSA and adverse pregnancy and fetal outcomes, such as GDM, preeclampsia, preterm birth, and neonatal low weight.9–11 Some risk factors for OSA, including obesity and increasing age, are shared by GDM. In addition, there is growing evidence that OSA is an independent risk factor for type 2 diabetes, and it has an adverse impact on glycemic control.12

There are several previous studies that evaluated the association between GDM and OSA, but most of them relied on self-related OSA symptoms,13 were retrospective,14,15 or did not measure electroencephalogram signals (EES).9,16 Moreover, reported findings have been inconsistent. Poor sleep quality as well as disturbed sleep at some time points are extremely common during pregnancy,17 but very few studies with polysomnography (PSG), the gold standard for the diagnosis of OSA during pregnancy,7 have been published, and they showed contradictory results.18–21 Furthermore, most of them were limited because they included small samples with high-risk pregnant women, mostly with obesity. Methodological differences, in terms of sleep assessment procedures, and study population may have contributed to the inconsistent findings of the relationship between OSA and GDM. Therefore more studies with attended PSG are clearly needed to clarify the influence of important confounding factors such as obesity, age, ethnicity, and comorbidities.

To address these limitations, we designed a case control study to compare the prevalence of OSA detected with PSG between patients with GDM and a control group of glucose-tolerant pregnant women. Moreover, we aimed to assess the potential association between OSA and GDM determinants. Lastly, we explored the relationships between sleep characteristics and carbohydrate metabolism.

MethodsStudy design and participants

We performed a multicentre case-control study at three tertiary and university hospitals namely Son Espases; Miguel Servet; and Araba, all in Spain. We selected as cases consecutive singleton adult pregnant women in the third trimester (3T) with GDM. GDM diagnosis was made according to the fasting 3-h 100-g glucose tolerance testing.22 As controls, we randomly selected adult pregnant women in the 3T without GDM. Subjects were excluded if they fulfilled at least one of the following exclusion criteria: (1) unwillingness or inability to participate in the study; (2) previous OSA; (3) previous diagnosis of diabetes mellitus, pulmonary, heart, or kidney diseases; (4) complicated pregnancy; (5) 50g oral glucose administration >140 before 24th gestation week; (6) multiple gestation; (7) treatment with systemic corticosteroids; (8) imminent delivery due to maternal-fetal disease; and/or (9) any other concurrent severe medical condition that would, in the investigator's judgment, contraindicate patient participation in the study.

The STROBE standards for reporting observational studies were followed. The Institutional Ethic Committee of the Balearic Islands approved the study (IB1510/10PI) and all subjects gave their written informed consent.

Laboratory researchers and study personnel were blinded to maternal status.

Clinical and sleep evaluation

Anthropometric, clinical, and sleep data, including Epworth Sleepiness Scale (ESS),23 were collected in all participants. Attended PSG was performed and manually scored using conventional criteria in each center.24,25 More detailed information is provided in supplemental material. Apnea-hypopnea index (AHI) was established as the number of apneas/hypopneas per hour of sleep. OSA was defined when AHI was ≥5h−1.26 Rapid eye movement (REM) AHI was calculated as the number of apneas/hypopneas during REM divided by total time in REM. AHI in supine was calculated as the number of apneas/hypopneas in supine divided by total sleep time (TST) in supine position. The mean SaO2 throughout the night, the minimum SaO2 (lowest values recorded during sleep), TST spent with SaO2<90% (T90), and the number of ≥3% drops in SaO2 per hour of sleep (desaturation index [DI]) were also computed.

Laboratory determinations

The morning after PSG, blood samples were collected in fasting conditions. Homeostasis model assessment of insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) were calculated by the usual formulas,27,28 More detailed information is provided in supplemental material.

Statistical analysis

Based on the previous description of an OSA prevalence of 15.4% in the third trimester of pregnancy,19 and accepting an alpha risk of 0.05 and a beta risk of 0.2 in a one-sided test without considering drop-outs during the crossover evaluation, 88 subjects were necessary in each group to detect as statistically significant a prevalence of at least twice higher in women with GDM.

Data are presented as mean±standard deviation or percentage. Differences between groups were analyzed using Student's t test for continuous variables and Fisher's exact test (two-tailed) or chi-squared test for categorical variables. To examine associations between groups and the variables, odds ratios (OR) and 95% confidence intervals (CI) in the univariate analyses were calculated. Correlations between variables were examined by Pearson's correlation. To identify independent relationships, those variables that reached statistical significance in the bivariate correlation analysis were then introduced in a stepwise multiple linear regression analysis together with anthropometric data (age, gestational weight gain, body mass index, neck circumference, and waist–hip ratio). Stepwise criteria were a probability of the F-distribution test to enter <0.05 and a probability of the F-distribution test to remove >0.10. The assumptions of linearity and distributional normality were controlled for all variables. Homoscedasticity was explored by scatter plots of the standardized residuals against standardized predicted values and by Levene's test for equality of variances. A two-sided p value less than 0.05 was considered significant. The statistical software used was SPSS v.26 (IBM).

ResultsStudy subjects’ characteristics

Fig. 1 presents the CONSORT flow chart of study subjects. From a total of consecutive 274 pregnant women considered, finally 89 newly diagnosed patients with GDM and 88 control pregnant women were included. Included women were mainly Caucasian (n=157, 89%) and nulliparous (n=117, 67%), with a mean±SD age of 34±4 years, and 18 (10.2%) had obesity (body mass index [BMI]30kg/m2) before gestation. Among the GDM participants, 33 (37.1%) required treatment with insulin, 3 (3.4%) were treated only with oral hypoglycemic agents, and 53 (59.6%) were diet-controlled.

Fig. 1.

Flow chart of study subjects in GDM and control pregnant women. Abbreviations: GDM: gestational diabetes mellitus.


The main demographic, clinical, and functional characteristics are shown in Table 1. Patients with GDM had greater pre-gestational and gestational BMI; however, weight gain at 3T was higher among control women. Moreover, neck circumference was significantly higher in GDM patients compared with control pregnant women. The remaining anthropometric characteristics, smoking and alcohol drinking, physical examination, and blood pressure were similar in GDM and control groups.

Table 1.

Clinical and functional characteristics of the study subjects.

  Gestational diabetes mellitus (n=89)  Control pregnant women (n=88)  p value 
Age, yr  35±34±0.10 
Gestational age, weeks  34.5±3.0  33.6±3.1  0.059 
Caucasian ethnicity, n (%)  78 (87.6)  79 (90.8)  0.326 
First pregnancy, n (%)  47 (54.0)  48 (54.5)  0.694 
Pregestational body mass index, kg/m2  25.6±22.9±3.2  0.00 
Pregestational obesity, n (%)  15 (16.9)  3 (3.5)  0.00 
Gestational weight gain, kg  8.5±11.3±4.4  0.00 
Gestational body mass index, kg/m2  28.8±4.8  26.9±2.9  0.00 
Pregestational smokers, %  27.3  22.7  0.215 
Pack/yr  3.6±5.3  4.2±8.1  0.598 
Neck circumference, cm  34.4±33.5±2.3  0.03 
Waist–hip ratio  1±0.07  0.99±0.05  0.184 
Mallampati, n (%)      0.416 
Class I  23 (26.4)  27 (31.4)   
Class II  22 (25.3)  28 (32.6)   
Class III  17 (19.5)  14 (16.3)   
Class IV  25 (28.7)  17 (19.8)   
Micrognatia, %  2.4  5.8  0.227 
High arched palate, %  5.9  1.2  0.103 
Enlarged uvula, %  4.7  0.059 
Large soft palate; %  3.5  1.2  0.306 
Tonsillar hypertrophy  2.4  2.3  0.685 
Gestational smokers, %  11.2  0.056 
Pregestational alcohol intake, g/day  0.98±1.1±0.891 
Systolic BP, mmHg  109±12  106±10  0.060 
Diastolic BP, mmHg  67±65±0.192 
Glucose, mg/dL  76±76±0.832 
Cholesterol, mg/dL  258±52  273±50  0.051 
Triglycerides, mg/dL  226±99  203±83  0.104 
HDL cholesterol, mg/dL  67.5±22.8  76.2±33.8  0.047 
Triglycerides/HDL cholesterol  3.7±2.3  2.9±1.3  0.006 
Urea, mg/dL  21.1±6.4  17.8±4.7  0.000 
Aspartate aminotransferase, U/L  21.5±13  17.8±7.9  0.042 
Hemoglobin A1c, %  5.3±0.8  5.3±1.1  0.867 
Insulin, μUI/mLa  12.1±7.0  11.9±5.1  0.817 
HOMA-IRa  2.3±1.4  2.2±1.1  0.901 
QUICKIa  0.35±0.04  0.34±0.02  0.334 
Cortisol, mg/dL  23.2±6.1  25.0±7.2  0.089 
Fibrinogen, mg/dL  640±101  592±76  0.001 
Hemoglobin, g/dL  12.1±1.1  11.7±0.9  0.003 
Leucocytes, 103/uL  8.5±2.1  9.4±2.1  0.006 
Platelets, 103/uL  215±58  229±54  0.098 

Values represent mean±SD or percentage. Abbreviations: Hemoglobin A1c, glycated hemoglobin HOMA-IR, homeostasis model assessment of insulin resistance; BP, blood pressure. QUICKI, Quantitative Insulin sensitivity check index.


Only in pregnant women without insulin treatment, n=145.

There were not significant differences in glycated hemoglobin, insulin, cortisol levels, HOMA-IR, and QUICKI between GDM patients and control women. However, pregnant women with GDM had higher ratio of triglycerides to high-density lipoprotein cholesterol (HDL) and lower HDL cholesterol than control women. Moreover, urea, aspartate aminotransferase, and fibrinogen levels were significantly higher in GDM patients than in control women. Besides, we also found significant differences in hemoglobin and leucocytes count in patients with GDM compared with normal pregnant women, although mean values were within normal limits (Table 1).

Sleep characteristics

No significant differences in OSA symptoms between patients with GDM and control subjects were found (Table 2). There were no differences in self-reported sleep time on weekdays and reported naptime, but self-reported sleep time on weekends was slightly higher in patients with GDM than in the control group (Table 2). Minimum SaO2 was lower in the GDM group (90.8±5.3% vs. 92.3±3.1%, p=.027). Although mean and maximum obstructive apneas duration were longer in GDM patients, AHI and the remaining sleep parameters were similar among both groups (Table 3).

Table 2.

Sleep apnea related symptoms.

  Gestational diabetes mellitus (n=89)  Control pregnant women (n=88)  p value 
Snoring      0.746 
Never (%)  40.9  44.8   
Sometimes (%)  27.3  31.0   
Usually (%)  13.7  11.4   
Always (%)  18.2  12.6   
Reported apnea      0.327 
Never (%)  87.1  94.2   
Sometimes (%)  10.6  5.8   
Usually (%)  1.2   
Always (%)  1.2   
Frequent awakenings      0.980 
Never (%)  78.4  79.5   
Sometimes (%)  18.2  17   
Usually (%)  3.4  3.4   
Always (%)   
Unrefreshing sleep      0.696 
Never (%)  43.7  36.5   
Sometimes (%)  33.3  32.9   
Usually (%)  17.2  21.2   
Always (%)  5.7  9.4   
Morning headache      0.846 
Never (%)  85.2  82.8   
Sometimes (%)  12.5  12.6   
Usually (%)  2.2  3.4   
Always (%)  1.1   
Nocturia      0.328 
Never (%)  13.8  11.4   
Sometimes (%)  14.9  14.8   
Usually (%)  25.2  38.7   
Always (%)  45.0  35.2   
Sleepiness while driving      0.185 
Never (%)  96  91.1   
Sometimes (%)  8.9   
Table 3.

Sleep characteristics of the study subjects.

  Gestational diabetes mellitus (n=89)  Control pregnant women (n=88)  p value 
Epworth sleepiness scale  6±7±0.614 
ASDA scale      0.377 
No  42.3  50.6   
Mild  49.3  35.8   
Moderate  7.0  11.1   
Severe  1.4  2.5   
Reported sleep time/working days, h  7.2±1.2  6.9±1.4  0.162 
Reported sleep time/weekends, h  7.8±1.5  7.2±1.6  0.018 
Reported nap time/working days, mdaysmimin  23.8±30.8  26.8±36.6  0.579 
Reported nap time/weekends, min  38.3±38.4  31.4±40.6  0.253 
Total sleep time, min  308±62  309±75  0.918 
Sleep efficiency, %  72.3±14.1  70.3±15.8  0.388 
N1+N2 sleep time, %  57.1±20.5  59.6±17.5  0.381 
N3 sleep time, %  31.2±20.3  27.5±17.9  0.199 
REM sleep time, %  11.7±5.7  13.0±5.4  0.133 
Apnea-hypopneas index, h−1  3.2±6.0  1.9±2.7  0.069 
Obstructive apneas duration, s  6.4±15  2.7±6.2  0.034 
Maximum obstructive apneas length, s  7.5±19  2.8±7.3  0.032 
Apnea-hypopneas duration, s  20.9±14.9  20.8±14.4  0.981 
Maximum apnea-hypopneas length  35.1±27.6  33.3±23.08  0.648 
Obstructive apneas index, h−1  0.5±2.3  0.07±0.18  0.112 
Central apneas index, h−1  0.16±0.49  0.13±0.29  0.708 
Mixed apneas index, h−1  0.09±0.3  0.04±0.2  0.241 
Arousal index, h−1  15.6±14.2  13.7±11.8  0.351 
Supine apnea-hypopneas index, h−1  2.7±4.7  2.5±4.0  0.875 
REM apnea-hypopneas index, h−1  7.3±15.5  4.1±7.1  0.080 
Mean SaO2, %  96±96±0.813 
Minimum SaO2, %  91±92±0.027 
T90, min  0.48±0.66±2.9  0.640 
Desaturation index, h−1  1.0±3.0  0.7±1.5  0.287 

Values represent mean±SD or percentage. Abbreviations: REM, rapid eye movement; SaO2, oxygen saturation; T90, total sleep time in minutes spent with SaO2<90%.

Prevalence of OSA in study groups

In the GDM group, 14.6% of women (n=13) had mild OSA, 3.4% (n=3) had moderate OSA, and 1.1% (n=1) had severe OSA. Among controls, 12.5% (n=11) had mild OSA. Fig. 2 shows the prevalence of an at least mild (AHI>5h−1), moderate (AHI>15h−1), and symptomatic (AHI>5h−1 and EES11) OSA in both groups. Besides, we illustrated the prevalence of REM and supine OSA. We did not find significant differences in percentages of associated OSA in any of the severity groups, neither in the specific supine OSA prevalence nor in the REM OSA prevalence among the study groups.

Fig. 2.

Prevalence of obstructive sleep apnea in GDM and control pregnant women. Abbreviations: AHI: apnea hypopnea syndrome; ESS: Epworth sleepiness scale; GDM: gestational diabetes mellitus; REM: rapid eye movement.

Association between OSA and GDM

We did not identify OSA as a GDM risk factor in the crude analysis. For several cutoffs, the AHI was not significantly associated with the presence of GDM (Fig. 2). An AHI>5h−1 had an odds ratio of 1.65 (95%CI: 0.73–3.77; p=.232) while an AHI in REM>5h−1 and an AHI in supine >5h−1 had crude odds ratios of 1.36 (95%CI: 0.71–2.58; p=.353) and 1.01 (95%CI: 0.43–2.39; p=.975), respectively. Additionally, the presence of an elevated AHI (>5h−1) and daytime hypersomnolence (ESS11) were not associated with GDM.

Relation between sleep characteristics and carbohydrate metabolism

In the overall study group, Glycated hemoglobin (hemoglobin A1c) was not related to sleep parameters. However, HOMA-IR, a surrogate marker of insulin resistance, was related to TST, REM sleep time, maximum duration of obstructive apneas, hypopneas index, AHI, maximum duration of apneas-hypopneas, T90, and DI (Table 4). Similarly, insulin sensitivity, which was assessed by QUICKI, was related with TST, arousal index, hypopnea index, AHI, maximum duration of apneas-hypopneas, and T90 (Table 4). All these variables, as well as age, gestational weight gain, pregestational body mass index, neck circumference, and waist–hip ratio, were included into a multiple regression model, which retained T90, TST, and maximum duration of respiratory events as independent factors related to HOMA-IR, while T90 was the only independent determinant of insulin sensitivity (Table 5).

Table 4.

Relationship between insulin resistance or sensitivity and sleep parameters in pregnant women, excluding patients with gestational diabetes mellitus with insulin treatment.

  Correlation coefficientp value  Correlation coefficientp value 
  r  95%CI    r  95%CI   
Total sleep time, min  −0.195  −0.350 to −0.030  0.021  0.214  0.050 to 0.367  0.011 
REM sleep time, %  −0.167  −0.324 to −0.001  0.049  –  –  – 
Arousal index, h−1  –  –  –  −0.171  −0.329 to −0.004  0.045 
Maximum obstructive apneas length, s  0.219  0.052 to 0.374  0.011  –  –  – 
Hipopneas index, h−1  0.240  0.077 to 0.390  0.004  −0.193  −0.348 to −0.028  0.022 
Apnea–hypopneas index, h−1  0.241  0.078 to 0.391  0.004  −0.194  −0.349 to −0.029  0.022 
Maximum apnea–hypopneas length, s  0.179  0.013 to 0.335  0.034  −0.176  −0.332 to −0.010  0.038 
T90, min  0.358  0.204 to 0.495  <0.001  −0.220  −0.372 to −0.056  0.009 
Desaturation index, h−1  0.210  0.046 to 0.363  0.013  –  –  – 

Abbreviations: HOMA-IR, homeostasis model assessment of insulin resistance; QUICKI, qualitative insulin sensitivity check index; REM, rapid eye movement; SaO2, oxygen saturation; T90, total sleep time spent with SaO2<90%.

Table 5.

Independent predictors of insulin resistance and sensitivity in pregnant women.a

  Unstandardized regression coefficientsStandardized regression coefficients  p value  R2 
  B  SE  95%CI  B     
T90, min  0.189  0.044  0.102 to 0.277  0.453  <0.001  0.139 
Total sleep time, min  −0.006  0.002  −0.010 to −0.003  −0.376  0.001  0.215 
Waist–hip ratio  −6.267  2.032  −10.329 to −2.205  −0.316  0.003  0.295 
Age, yr  −0.059  0.025  −0.108 to −0.010  −0.242  0.020  0.352 
Maximum apnea–hypopneas length, s  0.008  0.004  0.000 to 0.015  0.216  0.038  0.396 
Constant  11.974  2.386  7.204 to 16.743  –  –  – 
Pregestational BMI, kg/m2  −0.002  0.001  −0.003 to 0.000  −0.257  0.027  0.097 
T90, min  −0.002  0.001  −0.004 to 0.000  −0.231  0.046  0.147 
Constant  0.396  0.021  0.353 to 0.439  –  –  – 

Abbreviations: HOMA-IR, homeostasis model assessment of insulin resistance; QUICKI, qualitative insulin sensitivity check index; T90, total sleep time spent with SaO2<90%; BMI, body mass index.


In both models, age, gestational weight gain, pregestational body mass index, neck circumference, waist–hip ratio, and all sleep variables significantly that were correlated with HOMA-IR or QUICKI in the bivariate analysis were included.


The main findings of the present study are: (1) OSA prevalence during the 3T was not significantly different in patients with GDM than in glucose-tolerant pregnant women. (2) We did not find significant associations between OSA and GDM. (3) HOMA-IR showed an inverse relationship with TST, and a direct correlation with maximum duration of apnea-hypopneas, while there was a direct relationship between T90 and HOMA-IR, and QUICKI.

Most previous studies that have evaluated the relationship between GDM and OSA were based on OSA symptoms,13 were retrospective,14,15 or used type 2–3 sleep devices.16 Moreover, there are some meta-analyses evaluating this association, but with conflicting findings.29–32 Taking into account all these studies, and its inconsistent conclusions, it is still unclear the existence of an association between OSA and GDM. The largest prospective study of OSA in pregnancy until now successfully performed home type 3 sleep tests to 2474 women at late second or early 3T. The prevalence of pre-pregnancy obesity was 23.3%, whereas OSA prevalence was 8.4% in mid-pregnancy. GDM was detected in 96 women, which was independently associated with OSA after adjustment for age, BMI, chronic hypertension, and weight gain (OR: 2.79, CI: 1.63–4.77).9 However, this study was designed and powered to determine if OSA was a risk factor for preeclampsia. Additionally, as a secondary objective, the authors aimed to examine the association with GDM. Furthermore, some women were classified as GDM using medical record abstraction when glucose tolerance test were not available. Nonetheless, the main limitation acknowledged by the authors was that OSA was diagnosed with a home sleep-recording device without EEG variables, that is not validated in pregnancy, which underestimate the burden and severity of the disease, and it does not allow to measure important variables like sleep architecture, arousals, or REM sleep apneic episodes.

To our knowledge, there are only four studies that have evaluated the potential association between GDM and OSA employing PSG recordings, and they deserve some comments. Louis et al.19 performed home PSG in obese pregnant women (76% Afro-American/Hispanic-American), and OSA prevalence was 15.4%. GDM was detected in 17 of them, but the prevalence of GDM was similar among OSA and non-OSA women. Similar results were found in a small case-control study that included 26 women with GDM. All participants underwent unattended home PSG during 3T. GDM women had significant higher ESS compared with control subjects, but neither AHI nor OSA prevalence were significantly different among study groups.18 On the contrary, Retrakul et al.20 found a higher prevalence of OSA in a group of 15 patients with GDM compared with 15 non-diabetic controls (73 vs 27%, p=.01). This study is also limited because of its small sample size and the inclusion of mostly non-Caucasian women with obesity. In keeping with these results, a recently small case-control study performed PSG in 46 women with GDM and in 46 controls, who were matched for age, gestational age, BMI, race, and parity.21 The frequency of OSA was found to be higher in GDM cases than in controls (22 vs. 9%). OSA was found to be significantly associated with the risk of GDM (OR, 1.81). Nevertheless, the main limitation of this study was that mean pre-pregnancy BMI was 30kg/m2, maybe because they over-included subjects with overweight/obesity. Furthermore, more than 75% of them were Afro-American/Hispanic-American. Obesity, and the high percentage of the previously mentioned ethnic groups in the study samples, which are known risk factors for both GDM and OSA, might have an impact on the main findings,1,33 which makes difficult any generalization of their results. As far as we know, our study has included the largest number of pregnant women studied by PSG in the evaluation of OSA as a risk factor for GDM to date. Overall, obesity rate was 10.2%, and, as expected, we found that women with GDM had a higher BMI than controls, which represents the usual clinical finding of patients with GDM. Despite this fact, we did not find that neither AHI nor prevalence of OSA were different among the study groups.

The relationships between GDM and OSA are complex, and any interactions between contributing factors are still unclear. Obesity is one of the main determinants to GDM risk. Besides, ethnicity and age could play major roles.1,22 In study of 105 pregnant women (75% African-American, BMI=33.4), a 27% of OSA frequency has been reported, moreover, with every BMI increase of 5kg/m2, subjects were nearly two times more likely to have OSA.34 Hence, larger studies with PSG are needed to better clarify the complex interrelationships between OSA and GDM, as well as the influence of important cofounding factors, such as obesity, ethnic background, and maternal age.

Specific hormonal and physiological changes during pregnancy could lead to OSA.7,8 The mechanisms responsible for the potential association with GDM have been poorly explained. Among others, it has been proposed that intermittent hypoxia, and arousals could lead to an increase in systemic inflammation, in oxidative stress, and in sympathetic activation, which could contribute to increase cortisol secretion, promoting IR, impairing glucose uptake, and increasing gluconeogenesis.7,10,11,16 However, most evidence of these multiple mechanistic pathways has yet to be demonstrated whether they are also involved during pregnancy.

We did not find significant associations between arousal index and IR. Moreover, we did not find differences in AHI, but patients with GDM had longer mean and maximum obstructive apneas length, in addition to lower nocturnal minimum SaO2. Besides, HOMA-IR was related to maximum duration of respiratory events, and both HOMA-IR and QUICKI were directly proportional to CT90 independently of obesity. Longer sleep event duration has been previously associated with lower nocturnal SaO2 and longer CT90 in OSA.35 Similarly, other groups showed that nocturnal hypoxia markers correlated positively with fasting glucose levels,20,36 IR, and beta cell dysfunction.37 Based on these findings, nocturnal hypoxia could be a potential intermediate mechanism and a better factor in the complex relationship between glucose metabolism and OSA during pregnancy.38 However, a limited number of studies with very small samples, and some confounding variables have examined whether nocturnal hypoxia increases the risk of IR. The percentage of women with obesity was high in most studies, and it could also be possible that the increased risk may be related to obesity or other comorbidities and not to OSA per se.

Sleep time decreases during gestation, particularly by the 3T. Additionally, multifactorial aspects such as psychosocial, ethnic, physical, and biological factors predispose to worsen the sleep quality.17,39 There is some evidence that shorter sleep time is associated with higher glucose levels and GDM.40 We also found that objectively shorter TST was independently associated with higher HOMA-IR. Consequently, an alternative hypothesis is that sleep duration, as well as sleep quality not related to OSA, increases sympathetic activity41 and results in hypothalamic-pituitary-adrenal axis dysregulation,42 which could promote IR. Nonetheless, TST was based in only one night evaluation, and further studies are needed to explore this hypothesis.

Strengths of our study include a multicenter approach, a prospective enrolment, sufficient sample size, and the use of the same protocol in both cases and controls with an objective measure of sleep parameters with PSG performed at hospital. Additionally, laboratory researchers and study personnel were blinded to maternal status. Yet, a number of potential limitations deserve comment. First, the global refusal rate to participate was high (29%), which was though expectedly, as previous studies showed a similar and even much higher percentage of refusal rate (26–88%) both in GDM patients,18,19 and in other groups of pregnant women.7,30 The Institutional Ethic Committee did not allow the collection of information from those women who had declined participation, however we believe that the consecutive recruitment of patients, as well as the general and anthropometric characteristics of the selected women, similar to series of both GDM and healthy pregnant women from the same geographical area,43–45 suggest that the study sample could be considered as representative and makes it difficult to consider a selection bias. Second, as it is already known, we found patients with GDM had higher pregestational BMI. However, it is unlikely that this would modify our results to any important extent since obesity prevalence was relatively low (10%), and despite this, we did not find differences neither in AHI nor in OSA prevalence between both study groups. Third, since episodes of flow limitation <30% associated with arousal were not scored, we cannot ascertain whether our results would still be similar, though, it is unlikely to affect our conclusions as previous studies evaluating OSA in GDM and integrating flow limitation scoring, showed no remarkable influence, since the sleep time spent with flow limitation was similar in both groups in one of the studies,18 while the other study found that the flow limitation index was not associated with increased risk of GDM, spite of the fact the authors showed that OSA prevalence (based only in AHI) was significantly higher in GDM than in control pregnant women.21 Fourth, because we included mainly Caucasian women, our results may not be directly applicable to other ethnic groups. Fifth, further studies are required to better determine the influence of OSA, since the women with OSA of the present study mainly had very mild forms, which could limit further analysis to study the association between DGM and moderate-severe OSA. Finally, the design of the present study does not allow to determine whether OSA started previously or during early or late pregnancy.


In summary, our results did not demonstrate significant differences in OSA prevalence among patients with GDM and control pregnant women, and we did not find significant and independent associations between OSA and GDM. Nevertheless, we found that IR was negatively related with TST and positively related to respiratory apnea-hypopneas length, as well as nocturnal hypoxia, representing that OSA influence on IR during pregnancy could be more complex than its effect on AHI would implicate. The number of studies that have evaluated the interactions of OSA with GDM is still scarce, with major heterogeneity in research design, and populations included. Further, larger, multicenter, and more rigorous investigations employing PSG studies in all subjects, with attention to important confounding factors such as obesity, age and ethnic background, are clearly needed to better clarify and characterize the potential complex interrelationships between OSA and GDM,46 in the meantime, practitioners should screen and treat OSA in suspected pregnant women.


This research was partially supported by grants from SEPAR-2010-820, Ministerio de Economía y Competitividad (PI10/00495), Ministerio de Ciencia, Innovación y Universidades (PI19/00875), and Programa “Ramon Llull”, contractes per a la Intensificació de l’Activitat Investigadora a l’IdISBa 2020.

Conflict of interest

The authors declare that they have no conflict of interest.


We thank all women for their willingness to participate. The authors thank Meritxell-Arqué, for her assistance in the study fieldwork, and J. Rebolo-Roca for his language assistance.

ACOG practice bulletin no. 190: gestational diabetes mellitus.
M.M. Hedderson, M.A. Williams, V.L. Holt, N.S. Weiss, A. Ferrara.
Body mass index and weight gain prior to pregnancy and risk of gestational diabetes mellitus.
Am J Obstet Gynecol, 198 (2008), pp. 409
L. Marozio, E. Picardo, C. Filippini, E. Mainolfi, P. Berchialla, F. Cavallo, et al.
Maternal age over 40 years and pregnancy outcome: a hospital-based survey.
J Matern Fetal Neonatal Med, 32 (2019), pp. 1602-1608
C.G. Solomon, W.C. Willett, V.J. Carey, J. Rich-Edwards, D.J. Hunter, G.A. Colditz, et al.
A prospective study of pregravid determinants of gestational diabetes mellitus.
JAMA, 278 (1997), pp. 1078-1083
P.E. Peppard, T. Young, J.H. Barnet, M. Palta, E.W. Hagen, K.M. Hla.
Increased prevalence of sleep-disordered breathing in adults.
Am J Epidemiol, 177 (2013), pp. 1006-1014
J.E. Dominguez, L. Street, J. Louis, J. Dominguez.
Management of obstructive sleep apnea in pregnancy.
Obstet Gynecol Clin North Am, 45 (2018), pp. 233-247
S. Pamidi, R.J. Kimoff.
Maternal sleep-disordered breathing.
Chest, 153 (2018), pp. 1052-1066
B. Izci, R.L. Riha, S.E. Martin, M. Vennelle, W.A. Liston, K.C. Dundas, et al.
The upper airway in pregnancy and pre-eclampsia.
Am J Respir Crit Care Med, 167 (2003), pp. 137-140
F.L. Facco, C.B. Parker, U.M. Reddy, R.M. Silver, M.A. Koch, J.M. Louis, et al.
Association between sleep-disordered breathing and hypertensive disorders of pregnancy and gestational diabetes mellitus.
Obstet Gynecol, 129 (2017), pp. 31-41
S. Pamidi, L.M. Pinto, I. Marc, A. Benedetti, K. Schwartzman, R.J. Kimoff.
Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis.
Am J Obstet Gynecol, 210 (2014), pp. 52
K.K. Truong, C. Guilleminault.
Sleep disordered breathing in pregnant women: maternal and fetal risk, treatment considerations, and future perspectives.
Expert Rev Respir Med, (2018), pp. 177-189
E. Martínez Cerón, R. Casitas Mateos, F. García-Río.
Sleep apnea-hypopnea syndrome and type 2 diabetes. A reciprocal relationship?.
Arch Bronconeumol, 51 (2015), pp. 128-139
L.M. O’Brien, A.S. Bullough, J.T. Owusu, K.A. Tremblay, C.A. Brincat, M.C. Chames, et al.
Pregnancy-onset habitual snoring, gestational hypertension, and preeclampsia: prospective cohort study.
Am J Obstet Gynecol, 207 (2012), pp. 487
G. Bourjeily, V.A. Danilack, M.H. Bublitz, H. Lipkind, J. Muri, D. Caldwell, et al.
Obstructive sleep apnea in pregnancy is associated with adverse maternal outcomes: a national cohort.
Sleep Med, 38 (2017), pp. 50-57
J.M. Louis, M.F. Mogos, J.L. Salemi, S. Redline, H.M. Salihu.
Obstructive sleep apnea and severe maternal-infant morbidity/mortality in the United States, 1998–2009.
Sleep, 37 (2014), pp. 843-849
F.L. Facco, D.W. Ouyang, P.C. Zee, A.E. Strohl, A.B. Gonzalez, C. Lim, et al.
Implications of sleep-disordered breathing in pregnancy.
Am J Obstet Gynecol, 210 (2014), pp. 559
L.M. Christian, J.E. Carroll, K. Porter, M.H. Hall.
Sleep quality across pregnancy and postpartum: effects of parity and race.
Sleep Health, 5 (2019), pp. 327-334
M. Bisson, F. Series, Y. Giguere, S. Pamidi, J. Kimoff, S.J. Weisnagel, et al.
Gestational diabetes mellitus and sleep-disordered breathing.
Obstet Gynecol, 123 (2014), pp. 634-641
J. Louis, D. Auckley, B. Miladinovic, A. Shepherd, P. Mencin, D. Kumar, et al.
Perinatal outcomes associated with obstructive sleep apnea in obese pregnant women.
Obstet Gynecol, 120 (2012), pp. 1085-1092
S. Reutrakul, N. Zaidi, K. Wroblewski, H.H. Kay, M. Ismail, D.A. Ehrmann, et al.
Interactions between pregnancy, obstructive sleep apnea, and gestational diabetes mellitus.
J Clin Endocrinol Metab, 98 (2013), pp. 4195-4202
B. Izci Balserak, G.W. Pien, B. Prasad, D. Mastrogiannis, C. Park, L.T. Quinn, et al.
Obstructive sleep apnea is associated with newly-diagnosed gestational diabetes mellitus.
Ann Am Thorac Soc, 17 (2020), pp. 754-761
W. Ricart, J. López, J. Mozas, A. Pericot, M.A. Sancho, N. González, et al.
Potential impact of American Diabetes Association (2000) criteria for diagnosis of gestational diabetes mellitus in Spain.
Diabetologia, 48 (2005), pp. 1135-1141
E. Chiner, J.M. Arriero, J. Signes-Costa, J. Marco, I. Fuentes.
Validation of the Spanish version of the Epworth Sleepiness Scale in patients with a sleep apnea syndrome.
Arch Bronconeumol, 35 (1999), pp. 422-427
R.B. Berry, R. Budhiraja, D.J. Gottlieb, D. Gozal, C. Iber, V.K. Kapur, et al.
Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine.
J Clin Sleep Med, 8 (2012), pp. 597-619
C. Iber, S. Ancoli-Israel, A.L. Chesson, S.F. Quan.
The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications.
The American Academy of Sleep Medicine;, (2007),
O. Mediano, N. González Mangado, J. Montserrat, M.L. Alonso-Álvarez, I. Almendros, A. Alonso-Fernández, et al.
Documento Internacional de Consenso sobre Apnea Obstructiva del Sueño.
Arch Bronconeumol, 58 (2022), pp. 52-68
M.J. Quon.
QUICKI is a useful and accurate index of insulin sensitivity.
J Clin Endocrinol Metab, 87 (2002), pp. 949-951
D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner.
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
Diabetologia, 28 (1985), pp. 412-419
X.-X. Ding, Y.-L. Wu, S.-J. Xu, S.-F. Zhang, X.-M. Jia, R.-P. Zhu, et al.
A systematic review and quantitative assessment of sleep-disordered breathing during pregnancy and perinatal outcomes.
Sleep Breath, 18 (2014), pp. 703-713
L. Liu, G. Su, S. Wang, B. Zhu.
The prevalence of obstructive sleep apnea and its association with pregnancy-related health outcomes: a systematic review and meta-analysis.
Sleep Breath, 23 (2019), pp. 399-412
M.A. Luque-Fernandez, P.A. Bain, B. Gelaye, S. Redline, M.A. Williams.
Sleep-disordered breathing and gestational diabetes mellitus: a meta-analysis of 9,795 participants enrolled in epidemiological observational studies.
Diabetes Care, 36 (2013), pp. 3353-3360
T. Xu, Y. Feng, H. Peng, D. Guo, T. Li.
Obstructive sleep apnea and the risk of perinatal outcomes: a meta-analysis of cohort studies.
Sci Rep, 4 (2014), pp. 6982
K. Hnin, S. Mukherjee, N.A. Antic, P. Catcheside, C.L. Chai-Coetzer, D. McEvoy, et al.
The impact of ethnicity on the prevalence and severity of obstructive sleep apnea.
Sleep Med Rev, 41 (2018), pp. 78-86
G.W. Pien, A.I. Pack, N. Jackson, G. Maislin, G.A. Macones, R.J. Schwab.
Risk factors for sleep-disordered breathing in pregnancy.
S. Saraç, G.C. Afsar.
Effect of mean apnea-hypopnea duration in patients with obstructive sleep apnea on clinical and polysomnography parameter.
Sleep Breath, 24 (2020), pp. 77-81
S.N. Sökücü, L. Karasulu, L. Dalar, C. Ozdemir, E.C. Seyhan, S. Aydin, et al.
Effect of hypoxia on glucose metabolism in nondiabetic patients with obstructive sleep apnea syndrome.
Arch Bronconeumol, 49 (2013), pp. 321-325
E. Wanitcharoenkul, N. Chirakalwasan, S. Amnakkittikul, S. Charoensri, S. Saetung, S. Chanprasertyothin, et al.
Obstructive sleep apnea and diet-controlled gestational diabetes.
Sleep Med, 39 (2017), pp. 101-107
F.A. Camporro, G.V. Kevorkof, D. Alvarez.
Sleep-disordered breathing: looking beyond the apnea/hypopnea index.
Arch Bronconeumol, 55 (2019), pp. 396-397
J.A. Mindell, R.A. Cook, J. Nikolovski.
Sleep patterns and sleep disturbances across pregnancy.
Sleep Med, 16 (2015), pp. 483-488
F.L. Facco, W.A. Grobman, K.J. Reid, C.B. Parker, S.M. Hunter, R.M. Silver, et al.
Objectively measured short sleep duration and later sleep midpoint in pregnancy are associated with a higher risk of gestational diabetes.
Am J Obstet Gynecol, 217 (2017), pp. 447
A.V. Nedeltcheva, L. Kessler, J. Imperial, P.D. Penev.
Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance.
J Clin Endocrinol Metab, 94 (2009), pp. 3242-3250
M. O’Keeffe, M.-P. St-Onge.
Sleep duration and disorders in pregnancy: implications for glucose metabolism and pregnancy outcomes.
Int J Obes (Lond), 37 (2013), pp. 765-770
M.D.M. Roca-Rodríguez, C. López-Tinoco, Á. Fernández-Deudero, M. Murri, M.V. García-Palacios, M.D.A. García-Valero, et al.
Unfavorable cytokine and adhesion molecule profiles during and after pregnancy, in women with gestational diabetes mellitus.
Endocrinol Diabetes Nutr, 64 (2017), pp. 18-25
S. Civantos, M. Durán, B. Flández, M. Merino, C. Navea, G. Guijarro, et al.
Predictors of postpartum diabetes mellitus in patients with gestational diabetes.
Endocrinol Diabetes Nutr, 66 (2019), pp. 83-89
M.A. Guillén-Sacoto, B. Barquiel, N. Hillman, M.Á. Burgos, L. Herranz.
Gestational diabetes mellitus: glycemic control during pregnancy and neonatal outcomes of twin and singleton pregnancies.
Endocrinol Diabetes Nutr, 65 (2018), pp. 319-327
O. Mediano, I. Cano-Pumarega, M. Sánchez-de-la-Torre, M.L. Alonso-Álvarez, M.F. Troncoso, F. García-Río, et al.
Upcoming scenarios for the comprehensive management of obstructive sleep apnea: an overview of the Spanish Sleep Network.
Arch Bronconeumol, 56 (2020), pp. 35-41
Archivos de Bronconeumología
Article options

Are you a health professional able to prescribe or dispense drugs?